Alyeska Investment Group
TNXP icon

Alyeska Investment Group’s Tonix Pharmaceuticals TNXP Stock Holding History

Alyeska Investment Group’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-625
Closed -$43.6K – 685
2024
Q2 		$43.6K Hold
625
– – ﹤0.01% 549
2024
Q1 		$372K Sell
625
-220
-26% -$237K ﹤0.01% 436
2023
Q4 		$1.09M Buy
+845
New +$1.36M 0.01% 406

Other funds holding TNXP

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Alyeska Investment Group's TNXP Position: Q3 2024 in Review

Alyeska Investment Group sold out of Tonix Pharmaceuticals (TNXP) in Q3 2024, closing a stake of 625 shares — an estimated $43.6K sold.

Alyeska Investment Group first reported a position in TNXP in Q4 2023 and held it in 3 quarters. The position peaked at $1.09M in Q4 2023. 16 funds tracked by Wall St. Rank hold TNXP as of Q3 2024.

  • Alyeska Investment Group reported no remaining Tonix Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 625 Tonix Pharmaceuticals shares in Q3 2024, an estimated $43.6K.
  • Alyeska Investment Group first reported a position in Tonix Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Alyeska Investment Group's Tonix Pharmaceuticals position peaked at $1.09M in Q4 2023.
  • 16 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.